Bruce R. Rowley

5.3k total citations · 1 hit paper
7 papers, 950 citations indexed

About

Bruce R. Rowley is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Bruce R. Rowley has authored 7 papers receiving a total of 950 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 3 papers in Immunology and 2 papers in Oncology. Recurrent topics in Bruce R. Rowley's work include Monoclonal and Polyclonal Antibodies Research (2 papers), T-cell and B-cell Immunology (2 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). Bruce R. Rowley is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (2 papers), T-cell and B-cell Immunology (2 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). Bruce R. Rowley collaborates with scholars based in United States, Germany and Canada. Bruce R. Rowley's co-authors include Joseph B. Bolen, William Pao, Alec M. Cheng, Tony Pawson, Adrian Hayday, Daljeet Banwatt, David A. Clark, Manuel Jiménez‐Estrada, K C Flanders and Claudia Schneider and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The Journal of Immunology.

In The Last Decade

Bruce R. Rowley

7 papers receiving 932 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Syk tyrosine kinase required for mouse viability and B-cell development

1995 535 citations Alec M. Cheng, Bruce R. Rowley et al. Nature profile →

Peers

Bruce R. Rowley

IMMUN

MB

GENET

ONCOL

RNMI

Erica N Evans United States

Junko Ohata Japan

Cathy Quilici Australia

G Biron Canada

Timothy J. O rsquo Brien United States

Andrea G.S. Buggins United Kingdom

Cecilia Muñoz‐Calleja Spain

H Mitsui Japan

Laki Buluwela United Kingdom

Ingrid A. M. Derks Netherlands

Erica N Evans United States

Bruce R. Rowley

379 ×0.7

IMMUN

487 ×1.5

MB

288 ×1.6

GENET

187 ×1.1

ONCOL

80 ×0.7

RNMI

Citations per year, relative to Bruce R. Rowley Bruce R. Rowley (= 1×) peers Erica N Evans

Countries citing papers authored by Bruce R. Rowley

Since Specialization

Citations

This map shows the geographic impact of Bruce R. Rowley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce R. Rowley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce R. Rowley more than expected).

Fields of papers citing papers by Bruce R. Rowley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruce R. Rowley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce R. Rowley. The network helps show where Bruce R. Rowley may publish in the future.

Co-authorship network of co-authors of Bruce R. Rowley

This figure shows the co-authorship network connecting the top 25 collaborators of Bruce R. Rowley. A scholar is included among the top collaborators of Bruce R. Rowley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruce R. Rowley. Bruce R. Rowley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Liu, Ningshu, Bruce R. Rowley, Cathy Bull, et al.. (2013). BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models. Molecular Cancer Therapeutics. 12(11). 2319–2330. 206 indexed citations

2.

Liu, Ningshu, Bruce R. Rowley, Claudia Schneider, et al.. (2010). Abstract 4476: BAY 80-6946, a highly selective and potent pan class I PI3K inhibitor induces tumor apoptosis in vitro and tumor regression in vivo in a sub-set of tumor models. Cancer Research. 70(8_Supplement). 4476–4476. 2 indexed citations

3.

Wang, Xi-De, Bruce R. Rowley, Hewei Li, et al.. (2009). Abstract C18: Assessment of Gli1 expression during skin regeneration in mouse models and normal healthy volunteers. Molecular Cancer Therapeutics. 8(12_Supplement). C18–C18. 1 indexed citations

4.

Kellar, Kristen A., Matthew V. Lorenzi, Dan You, et al.. (2006). Constitutively active receptor tyrosine kinases as oncogenes in preclinical models for cancer therapeutics. Molecular Cancer Therapeutics. 5(6). 1571–1576. 5 indexed citations

5.

Pao, William, Alec M. Cheng, John M. Lewis, et al.. (1996). Disruption of epithelial gamma delta T cell repertoires by mutation of the Syk tyrosine kinase.. Proceedings of the National Academy of Sciences. 93(18). 9704–9709. 67 indexed citations

6.

Cheng, Alec M., Bruce R. Rowley, William Pao, et al.. (1995). Syk tyrosine kinase required for mouse viability and B-cell development. Nature. 378(6554). 303–306. 535 indexed citations breakdown →

7.

Clark, David A., et al.. (1990). Murine pregnancy decidua produces a unique immunosuppressive molecule related to transforming growth factor beta-2.. The Journal of Immunology. 144(8). 3008–3014. 134 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact